【4502】武田薬品工業 : Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia, Vipdomet and Incresync

Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia, Vipdomet and Incresync

出所:株経通信(株式会社みんかぶ)
PDFをダウンロード